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Hazardous Drug Exposure in Healthcare 
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Hazardous drug exposure in healthcare is a growing concern for the pharma industry and workers. 
Significant risks may be present including cancers for those handling and compounding various 
therapeutic agents. Workplace exposure standards do not exist for those employed in the pharma 
industry. Recommendations of safety have used the, ‘As Low as Reasonably Achievable’ (ALARA) 
principle to control exposures for pharmacists and others that handle hazardous substances. Steps should 
be taken to systematically eliminate and/or minimize exposures to workers through safer handling 
protocols, approved safety cabinets, negative pressure rooms, local exhaust ventilation, health 
surveillance, training and appropriate PPE. 
 
 




Antineoplastic drugs are used to treat more than 
12.1 million individuals diagnosed with cancer 
worldwide each year (Graeve, Mcgovern, 
Alexander, Church, Ryan, and Polovich, 2017). 
According to NIOSH, approximately 8 million 
U.S. health care workers are potentially exposed 
to a multitude of hazardous drugs in the 
workplace (NIOSH, 2016). The drugs have been 
detected in the urine of workers and on the floors 
and counters of worksites (Randolph, 2012). 
Chemotherapy (antineoplastics) drugs, 
hormones, antivirals, as well as some 
monoclonal antibodies and other miscellaneous 
drugs are classified as a hazardous drug. They 
are used to treat cancers, human 
immunodeficiency virus (HIV) and some 
autoimmune diseases (Müller-Ramírez, Squibb 
and Mcdiarmid, 2017). As new drugs are 
developed to treat the numerous cancers and 
other diseases, the health effects and the toxicity 
of these drugs is not usually known. These drugs 
must be handled using special precautions not 
only by health care professionals, but by those 
who work in these facilities as well. Although 
the hazards associated with hazardous drugs are 
recognized, there is not an acceptable exposure 




The health risks and toxicity associated with 
antineoplastic drugs are well understood.  
 
The International Agency for Research on 
Cancer (IARC) has classified antineoplastic 
drugs into three groups: Group 1 - carcinogenic 
to humans; Group 2a - probably carcinogenic to 
humans and: Group 2b - possibly carcinogenic 
to humans (Graeve, Mcgovern, Alexande, 
Church, Ryan, and Polovich, 2017).  NIOSH 
(2004) stated that there are approximately 140 
agents that fit the definition of a hazardous drug. 
Two-thirds of the hazardous drugs are 
determined to be antineoplastic drugs. Terms 
commonly known to describe the drugs are 
“antineoplastic” and “cytotoxic”. “Hazardous 
drugs” is a broader classification that can be used 
to describe the drugs. The NIOSH Alert glossary 
defines cytotoxic as “a pharmacologic 
compound that is detrimental or destructive to 
cells within the body” (NIOSH, 2004). The 
International Society of Oncology Pharmacy 
Practitioners (ISOPP) defines cytotoxic drugs as 
“chemicals that affect cell growth and 
proliferation, most of which either bind to 
genetic material in the cell nucleus or affect 
cellular proteins synthesis” (ISOPP, 2007). 
 
Health care workers are exposed on a repeated 
basis and experience side effects from these 
drugs that have no benefit to these individuals 
(Müller-Ramírez, Squibb and Mcdiarmid, 
2017). Previously, safe handling guidelines have 
only included cytotoxic or antineoplastic drugs 
regarding health care worker exposure. Now, it 
has been expanded to include all hazardous 
drugs. There has been evidence that indicates 
that health care workers are at risk from the 
 
73 
World Safety Journal. Vol. XXX. Issue 1




Prior studies have shown evidence of adverse 
health effects associated with exposure to 
antineoplastic drugs.  These effects include acute 
and chronic outcomes. Acute responses can be 
nausea, skin rashes, hair loss, nasal sores, 
abdominal pain, allergic reactions, and dizziness 
(Müller-Ramírez, Squibb and Mcdiarmid, 
2017). Chronic effects to hazardous drug 
exposures can be delayed conception time, 
spontaneous abortions, genotoxic changes, and 
cancers (Foxhall, 2009). Hospital personnel 
involved in preparation and administration of 
antineoplastic drugs may be at risk if exposed to 
these hazardous pharmaceuticals (Korczowska, 
Jankowiak-Gracz, Sessink, and Grzeskowiak, 
2013). If there is contamination in the 
environment that healthcare workers are present, 
we can assume that the workers are being 
exposed as well (Foxhall, 2009). Small 
exposures to such toxic drugs can have adverse 
outcomes on the health of the healthcare worker. 
Most exposures occur in hospitals and oncology 
facilities during administration of the drugs and 
the compounding process in the pharmacy. The 
occupational risk for health care workers is 
unacceptable (Graeve, Mcgovern, Alexande, 
Church, Ryan, and Polovich, 2017). 
 
Hazardous drugs can have multiple ways of 
getting into the body of a healthcare worker. 
They can be absorbed through inhalation, skin 
contact, ingestion from hand-to-mouth and 
injection. The main routes for exposure are 
believed to be inhalation and ingestion. 
Currently, it is not possible to establish a safe 
occupational exposure limit to these drugs. Any 
preventable occupational exposures should be 
avoided if possible and follow the “As Low as 
Reasonably Achievable” (ALARA) standard 
(Müller-Ramírez, Squibb and Mcdiarmid, 
2017). 
 
Healthcare workers and risk control 
The University of Minnesota researchers 
conducted a study of 163 oncology health care 
workers to determine factors that could 
contribute to workplace exposure. The objective 
of the study was to identify possible exposures, 
as well as determining factors that direct the 
safety behaviour of employees. The study also 
conducted environmental hazardous drug wipe 
sampling on surfaces present in the workplace. 
There was surface contamination in areas that 
personal protective equipment was not expected 
to be used, which can lead to potential exposure 
(Graeve, McGovern, Alexander, Church, Ryan, 
and Polovich, 2017).  
 
Many health care facilities that handle hazardous 
drugs have adopted the hierarchy of controls. 
The NIOSH Hierarchy of Controls has been 
identified and can be applied to this health care 
and the handling of hazardous drugs. These areas 
covered in the hierarchy of controls include 
elimination; substitution; engineering controls; 
administrative controls; and personal protective 
equipment. The basis behind the hierarchy of 
controls is that it uses a top-down methodology 
meaning that the most effective and protective 
are at the top and less effective and protective are 
at the bottom. Elimination of the hazard 
(material or process) is the most effective yet 
most difficult to implement in any process. In the 
instance of hazardous drugs, elimination is not 
possible, therefore diligent use of PPE, proper 
use of engineering controls and implementation 
of administrative control must be used. 
Substitution has the same issues as elimination.  
 
In healthcare, substitution with a less hazardous 
drug is not possible. Patients are placed on 
treatments that work for their disease. 
Engineering controls are the first level that can 
be used in health care settings because of their 
designation to remove the hazard before it is in 
contact with health care personnel. Finally, 
administrative controls and personal protective 
equipment (PPE) is used when the exposures are 
not well controlled. 
 
The first step is the engineering controls. When 
a hazard cannot be eliminated, an engineering 
control is recommended for use. In the case of 
compounding hazardous drugs, it should always 
be used for product and worker protection. 
Examples of engineering controls that provide 
worker and product protection are Class II and 
III biological safety cabinets (BSC) that are 
properly ducted with either a canopy or direct 
connection to an exhaust or a compounding 
aseptic containment isolator (CACI) that is 
exhausted to the outside. These engineering 
controls are placed within a controlled 
cleanroom environment that is negative 
pressure. The negative pressure cleanroom suite 
has pressure in the range of -0.01 to -0.03 inches 
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water column (in. w. c.) and exhausted to the 
outside, as well. This is considered a secondary 
engineering control (SEC) (USP Chapter <800>, 
2017). These primary engineering controls are 
often referred to as “hoods” in which the 
compounding activities are performed. They 
provide both product protection with an ISO 
Class 5 environment inside of the biological 
safety cabinet, as well as worker protection since 
the engineering control provides containment.  
 
Another level of protection to use both for 
compounding and administration is the use of a 
closed system transfer device (CTSD). This 
system is needleless and attaches together to 
transfer the hazardous drug between the vial to 
IV bag without any exposure. It is an extra level 
of protection if used within a BSC or CACI. 
With regards to CTSDs, some facilities consider 
them as a secondary engineering control used 
within a primary engineering control when 
compounding and mixing hazardous drugs, to 
reduce the risk and exposure to the hazardous 
drug. Others consider a CTSD as PPE (Mathias, 
2019). The U.S. Pharmacopeia (USP) 
recommends CTSD for compounding hazardous 
drugs and defines them as mandatory for 
administration of hazardous drugs (USP Chapter 
800, 2017).  
 
Next, the implementation of administrative 
controls should be used to help with guidance on 
processes within the health care facility. Some of 
the administrative controls are to use medical 
surveillance, training for employees who handle 
these drugs, cleaning, and decontamination of 
work surface sand disposal of hazardous drugs.  
PPE used to compound and any waste from 
compounding/ administration in the right waste 
containers (black or yellow), disinfect and 
deactivate the primary engineering controls 
(BSCs or CACIs), store hazardous drugs alone 
in a negative pressure room, define processes for 
unpacking shipping totes that have hazardous 
drugs, define a list of all hazardous drugs within 
the facility, etc. The administrative controls 
define processes that should be implemented 
within the facility to lower the exposure risk 
(Couch, West, and Niemeier, 2013). 
 
A list of all the drugs used in the facility should 
be compared to the list to the drugs on the 
NIOSH List of Antineoplastic and Other 
Hazardous Drugs in Healthcare Settings should 
be created and made accessible to all the 
personnel for staff that could possibly be in 
contact with these drugs. It is important to 
identify which departments and/or personnel 
could potentially handle or contact the hazard 
(ISOPP, 2007). Once the hazardous drugs in a 
facility have been identified, an assessment of 
risk should be completed by identifying the path 
that the hazardous drugs follow from when they 
enter the facility to when they leave as patient 
waste, contaminated laundry, IV bags, 
contaminated medical equipment etc. All 
potential sources of exposure should be 
identified. It is also important to identify all 
individuals who have the potential contact or 
handle hazardous drugs. Contamination of the 
environmental can be determined by surface 
sampling for hazardous drug residue. It is likely 
that any area where hazardous drugs are used 
could be contaminated by those drugs. The 
hazardous drug residue wipe sampling is only 
available for approximately 12 drugs that are 
used because they can indicate exposure to any 
of dozens of drugs the facility uses (ISOPP, 
2007).  
 
Personal protective equipment (PPE) is the last 
area within the NIOSH hierarchy of controls. 
With proper handling, as well as implementation 
of proper PPE such as double gloving, use of 
gloves rated by the American Society for Testing 
and Materials (ASTM) for chemotherapy, 
chemotherapy gowns made of polypropylene 
which have taped seams and coated by 
polyethylene on the outside to prevent liquids 
from seepage through and onto the healthcare 
worker, face shields to prevent splashing onto 
the face and into the eyes and the use of 
respirator protection, the incidence rate of 
exposure is reduced (Couch, West, and 
Niemeier, 2013). The amount of PPE donned is 
dependent upon the drug and the procedure 
involved with handling the hazardous drug 
(Tomkins, 2015).  CSTD systems can also be 
considered PPE and provide protection to the 
individuals handling these hazardous substances 
(Mathias, Mackenzie, Toennis, and Connor 
2019).  
 
Studies have shown that more workers are 
wearing gloves when handling hazardous drugs 
since the initial safe handling guidelines were 
implemented (Mathias, Mackenzie, Toennis, 
and Connor 2019).  However, a recent large 
study of health care workers conducted by 
 
75 
World Safety Journal. Vol. XXX. Issue 1
NIOSH (2016) found that one in seven of 2,069 
reported not always using gloves while handling 
hazardous agents. These studies determined that 
a lower rate of use in PPE was reported. A study 
of 165 nurses also found personal protective 
equipment (PPE) use varied by activity, with the 
lowest adherence to recommendations about the 
handling of patient excreta (Mathias, 
Mackenzie, Toennis, and Connor 2019).  
 
Currently, healthcare facilities and pharmacies 
that compound hazardous drugs are have a new 
guideline to follow for both non-sterile and 
sterile products. The United States 
Pharmacopeia released a new guideline, Chapter 
800, that was effective in most States, on July 
1st, 2019. All chapters in the USP Compounding 
Compendium under 1000 are enforceable by 
state boards of pharmacy. This chapter outlines 
safe handling, storage, compounding, room 
requirements, engineering controls and PPE 
requirements. The chapter was designed to be a 
guide to help facilities minimize and manage the 
drug exposures healthcare workers are exposed 
to, as well as give design elements for the rooms 
used for compounding. Previously, retail 
pharmacies had to follow USP Chapter 795 
regarding non-sterile compounding rules, 
however, with the implementation of Chapter 
800, it has now designated the same similar 
elements for pharmacies that compound non-
sterile hazardous drugs, such as estrogen and 




In conclusion, it is necessary to keep healthcare 
workers protected from hazardous drug 
exposures. Use of the proper engineering 
controls to keep the drugs contained when being 
stored, compounded, and administered is crucial 
to the health and well-being of these workers 
who are exposed daily. Policies and procedures 
designed around cleaning processes, proper PPE 
needs, waste disposal, medical surveillance, 
hazardous drug list, hazardous drug wipe 
sampling and continuing education are designed 
to help the individuals handling these drugs have 
specific operating procedures for their facilities 
needs that meet or exceed what should be done 
to protect the workers. It is mission critical to 
keep these workers safe. Without the 
implementation of the controls, more 
unnecessary exposures will occur which will 
lead to more adverse outcomes to the workers 
that are caring for some of the sickest patients. 
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